Nanox Imaging, an Israel-based radiology vendor, has announced potential financial distress, stating it may run out of cash within the year. As of September 30, the company reported approximately $26 million in cash and equivalents, down from $60 million at the end of 2025. The company warns that this amount is insufficient to sustain operations under current plans, raising doubts about its ability to continue as a viable entity. Nanox, which has faced manufacturing and regulatory challenges, has previously flagged financial concerns and is at risk of being delisted from Nasdaq. Despite forecasting revenues of up to $4.4 million for Q3 2026, largely from its teleradiology acquisition, the company will need to secure additional funding or may have to alter its product development strategy. Recently, it received recognition for its imaging device and signed a software distribution agreement in Italy.
Mon, 19 Oct 2026 10:12:39 GMT | Radiology Business